Review article · 2025 · Open access

Bile acids in metabolic dysfunction-associated steatotic liver disease

Enver Zerem, Suad Kunosić, Admir Kurtčehajić, Dina Zerem, Omar Zerem

World Journal of Hepatology, 17(8), 108606 · Published 27 August 2025 · DOI 10.4254/wjh.v17.i8.108606

Open PDFView at the publisherCite this paper

In brief

“Bile acids in metabolic dysfunction-associated steatotic liver disease” is a 2025 review article by Enver Zerem and 4 co-authors, published in World Journal of Hepatology. OpenAlex counts 18 citations as of 21 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at World Journal of Hepatology.

Citations
18
Most cited in
2026 (18)
Field-weighted impact
1.46
References
96
Authors
5

Abstract

The liver is a central metabolic organ that regulates numerous physiological processes, including glucose and lipid metabolism, detoxification, and the synthesis of essential proteins and bile. Bile acids (BAs), synthesized from cholesterol in hepatocytes, not only facilitate the emulsification and absorption of dietary fats but also act as potent signaling molecules through receptors such as the farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally, closely linked with obesity, insulin resistance, and other components of metabolic syndrome. In MASLD, the metabolism of BAs is markedly disrupted, resulting in alterations in their synthesis, composition, and signaling activity. These changes contribute to hepatic steatosis, inflammation, and fibrosis, thereby exacerbating metabolic dysfunction and liver damage. The altered profiles and signaling activity of BAs in MASLD patients suggest that BAs act not only as biomarkers of disease severity, but also as active mediators of its pathogenesis. Modulators of BA signaling pathways, especially FXR agonists, are the focus of intense research for their potential to beneficially influence liver steatosis and inflammation in MASLD. Recent research has yielded promising results, indicating potential therapeutic application and the introduction of novel agents aimed at modulating BA homeostasis and function. This minireview outlines the physiological roles of BAs, seeks to advance the elucidation of the mechanisms by which their dysregulation contributes to MASLD progression, and highlights current and emerging therapeutic approaches. A deeper understanding of these complex interactions is essential for improving the diagnosis, prognosis and treatment of MASLD.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zerem, E., Kunosić, S., Kurtčehajić, A., Zerem, D., & Zerem, O. (2025). Bile acids in metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology, 17(8), 108606. https://doi.org/10.4254/wjh.v17.i8.108606

MLA 9

Zerem, Enver, et al. “Bile acids in metabolic dysfunction-associated steatotic liver disease.” World Journal of Hepatology, vol. 17, no. 8, 2025, p. 108606. https://doi.org/10.4254/wjh.v17.i8.108606.

Chicago

Zerem, Enver, Suad Kunosić, Admir Kurtčehajić, Dina Zerem, and Omar Zerem. 2025. “Bile acids in metabolic dysfunction-associated steatotic liver disease.” World Journal of Hepatology 17 (8): 108606. https://doi.org/10.4254/wjh.v17.i8.108606.

Harvard

Zerem, E. et al. (2025) ‘Bile acids in metabolic dysfunction-associated steatotic liver disease’, World Journal of Hepatology, 17(8), p. 108606. doi:10.4254/wjh.v17.i8.108606.

IEEE

E. Zerem, S. Kunosić, A. Kurtčehajić, D. Zerem, and O. Zerem, “Bile acids in metabolic dysfunction-associated steatotic liver disease,” World Journal of Hepatology, vol. 17, no. 8, p. 108606, 2025, doi: 10.4254/wjh.v17.i8.108606.

BibTeX

@article{zerem2025bile,
  title     = {{Bile acids in metabolic dysfunction-associated steatotic liver disease}},
  author    = {Zerem, Enver and Kunosić, Suad and Kurtčehajić, Admir and Zerem, Dina and Zerem, Omar},
  journal   = {World Journal of Hepatology},
  year      = {2025},
  volume    = {17},
  number    = {8},
  pages     = {108606},
  doi       = {10.4254/wjh.v17.i8.108606},
  url       = {https://doi.org/10.4254/wjh.v17.i8.108606}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment

  • bile acids
  • non-alcoholic fatty liver disease
  • farnesoid X receptor
  • TGR5
  • bile acid signaling
  • hepatic steatosis
  • liver fibrosis
  • liver inflammation

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Zerem, E., Kunosić, S., Kurtčehajić, A., Zerem, D., & Zerem, O. (2025). Bile acids in metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology, 17(8), 108606. https://doi.org/10.4254/wjh.v17.i8.108606

How many times has this paper been cited?

18 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at World Journal of Hepatology: sign in and open the PDF from this page.

Who wrote this paper?

Enver Zerem, Suad Kunosić, Admir Kurtčehajić, Dina Zerem, Omar Zerem.

What is the DOI of this paper?

10.4254/wjh.v17.i8.108606, permanently at https://doi.org/10.4254/wjh.v17.i8.108606. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.